Cullinan Therapeutics, Inc.
US ˙ NasdaqGS ˙ US2300311063

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nadim Ahmed. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nadim Ahmed has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CGEM / Cullinan Therapeutics, Inc. President and CEO, Director 430,621
US:BMY / Bristol-Myers Squibb Company EVP and President, Hematology 0
US:CELG / Celgene Corp. PRES., GLOBAL HEM. AND ONC. 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nadim Ahmed. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CGEM / Cullinan Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CGEM / Cullinan Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-06-06 CGEM AHMED NADIM 8,090 12.4000 8,090 12.4000 100,316 43 15.4200 24,432 24.35

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insider Sales CGEM / Cullinan Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CGEM / Cullinan Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-02-25 CGEM AHMED NADIM 12,529 8.5300 12,529 8.5300 106,872 196 6.8300 -21,299 -19.93
2024-12-24 CGEM AHMED NADIM 8,400 11.8700 8,400 11.8700 99,708
2023-12-26 CGEM AHMED NADIM 4,272 9.2400 4,272 9.2400 39,473
2023-06-28 CGEM AHMED NADIM 759 11.4000 759 11.4000 8,653
2023-05-23 CGEM AHMED NADIM 707 9.1500 707 9.1500 6,469
2023-04-25 CGEM AHMED NADIM 716 10.5900 716 10.5900 7,582
2023-03-23 CGEM AHMED NADIM 706 10.5100 706 10.5100 7,420

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nadim Ahmed as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-02-27 2025-02-25 4 CGEM Cullinan Therapeutics, Inc.
Common Stock
S - Sale -12,529 430,621 -2.83 8.53 -106,872 3,673,197
2025-02-21 2025-02-19 4 CGEM Cullinan Therapeutics, Inc.
Common Stock
A - Award 180,000 443,150 68.40
2024-12-27 2024-12-24 4 CGEM Cullinan Therapeutics, Inc.
Common Stock
S - Sale -8,400 263,150 -3.09 11.87 -99,708 3,123,590
2024-02-23 2024-02-22 4 CGEM Cullinan Oncology, Inc.
Common Stock
A - Award 160,000 271,550 143.43
2023-12-27 2023-12-26 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -4,272 111,550 -3.69 9.24 -39,473 1,030,722
2023-06-29 2023-06-28 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -759 115,822 -0.65 11.40 -8,653 1,320,371
2023-05-24 2023-05-23 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -707 116,581 -0.60 9.15 -6,469 1,066,716
2023-04-26 2023-04-25 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -716 117,288 -0.61 10.59 -7,582 1,242,080
2023-03-27 2023-03-23 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -706 118,004 -0.59 10.51 -7,420 1,240,222
2023-02-23 2023-02-22 4 CGEM Cullinan Oncology, Inc.
Common Stock
A - Award 109,000 118,710 1,122.55
2022-07-05 2022-06-30 4 CGEM Cullinan Oncology, Inc.
Common Stock
A - Award 1,620 9,710 20.02 10.90 17,658 105,839
2022-06-07 2022-06-06 4 CGEM Cullinan Oncology, Inc.
Common Stock
P - Purchase 8,090 8,090 12.40 100,316 100,316
2022-03-07 2022-03-05 4 CGEM Cullinan Oncology, Inc.
Performance Stock Unit
A - Award 215,000 215,000
2021-10-20 2021-10-18 4 CGEM Cullinan Oncology, Inc.
Stock Option (Right to Buy)
A - Award 2,710,000 2,710,000
2021-01-05 2020-12-31 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise -14,946 0 -100.00
2021-01-05 2020-12-31 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -7,660 38,889 -16.46 62.03 -475,150 2,412,285
2021-01-05 2020-12-31 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 14,946 46,549 47.29
2020-12-03 2020-12-02 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise -6,594 19,782 -25.00
2020-12-03 2020-12-02 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -3,380 31,603 -9.66 62.18 -210,168 1,965,075
2020-12-03 2020-12-02 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 6,594 34,983 23.23
2020-11-03 2020-10-30 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise -4,650 0 -100.00
2020-11-03 2020-10-30 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -2,291 28,389 -7.47 58.45 -133,909 1,659,337
2020-11-03 2020-10-30 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 4,650 30,680 17.86
2020-05-05 2020-05-01 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise 2,908 0 -100.00
2020-05-05 2020-05-01 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -1,433 26,030 -5.22 60.26 -86,353 1,568,568
2020-05-05 2020-05-01 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 2,908 27,463 11.84
2020-03-12 2020-03-10 4 BMY BRISTOL MYERS SQUIBB CO
Performance Shares
A - Award 32,082 32,082
2020-03-12 2020-03-10 4 BMY BRISTOL MYERS SQUIBB CO
Market Share Units
A - Award 21,388 21,388
2020-03-03 2020-03-01 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise 17,204 34,410 99.99
2020-03-03 2020-03-01 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -8,473 24,555 -25.65 59.06 -500,415 1,450,218
2020-03-03 2020-03-01 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 17,204 33,028 108.72
2020-02-06 2020-02-04 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
M - Exercise 2,076 4,152 100.00
2020-02-06 2020-02-04 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
F - Taxes -1,071 15,824 -6.34 64.29 -68,855 1,017,325
2020-02-06 2020-02-04 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
M - Exercise 2,076 16,895 14.01
2020-01-03 2019-11-20 4/A BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 33,183 33,183
2020-01-03 2019-11-20 4/A BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 14,946 14,946
2019-12-04 2019-12-02 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 26,376 26,376
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 33,182 33,182
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 51,614 51,614
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 6,228 6,228
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 9,965 9,965
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 14,945 14,945
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 4,650 4,650
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Restricted Stock Units
A - Award 2,908 2,908
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 19,621 19,621
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 19,619 19,619
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 19,619 19,619
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,299 9,299
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,299 9,299
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,300 9,300
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 5,843 5,843
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 5,843 5,843
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 5,843 5,843
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 12,272 12,272
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 12,205 12,205
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 5,812 5,812
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,350 9,350
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,350 9,350
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,350 9,350
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 9,350 9,350
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 7,012 7,012
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 6,975 6,975
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 6,975 6,975
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 13,949 13,949
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 6,974 6,974
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 6,974 6,974
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 7,440 7,440
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 6,975 6,975
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 10,463 10,463
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 16,740 16,740
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 10,464 10,464
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 10,460 10,460
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Option (right to buy)
A - Award 3,255 3,255
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
A - Award 1,966 1,966
2019-11-27 2019-11-20 4 BMY BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value
A - Award 14,819 14,819
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
D - Sale to Issuer -27,749 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
D - Sale to Issuer -3,348 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
D - Sale to Issuer -5,357 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
D - Sale to Issuer -2,500 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
D - Sale to Issuer -1,563 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -10,549 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -10,548 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -10,548 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,125 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,125 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -6,563 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -6,562 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,125 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,125 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -7,500 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -4,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -3,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,626 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,626 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -9,000 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -5,624 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
D - Sale to Issuer -1,750 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Common Stock
D - Sale to Issuer -1,966 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Common Stock
D - Sale to Issuer -40,694 0 -100.00
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Common Stock
A - Award 17,840 40,694 78.06
2019-11-22 2019-11-20 4 CELG CELGENE CORP /DE/
Common Stock
A - Award 8,035 22,854 54.22
2019-11-04 2019-10-31 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
M - Exercise -3,281 0 -100.00
2019-11-04 2019-10-31 4 CELG CELGENE CORP /DE/
Common Stock
F - Taxes -1,096 14,819 -6.89 108.03 -118,401 1,600,897
2019-11-04 2019-10-31 4 CELG CELGENE CORP /DE/
Common Stock
M - Exercise 3,281 15,915 25.97
2019-05-06 2019-05-02 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
M - Exercise -1,563 0 -100.00
2019-05-06 2019-05-02 4 CELG CELGENE CORP /DE/
Common Stock
F - Taxes -490 12,634 -3.73 95.21 -46,653 1,202,883
2019-05-06 2019-05-02 4 CELG CELGENE CORP /DE/
Common Stock
M - Exercise 1,563 13,124 13.52
2019-03-05 2019-03-01 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
A - Award 27,749 27,749
2019-02-06 2019-02-04 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
A - Award 3,348 3,348
2018-12-18 2018-12-16 4 CELG CELGENE CORP /DE/
Restricted Stock Unit
M - Exercise -3,000 0 -100.00
2018-12-18 2018-12-16 4 CELG CELGENE CORP /DE/
Common Stock
F - Taxes -1,477 11,561 -11.33 68.20 -100,731 788,460
2018-12-18 2018-12-16 4 CELG CELGENE CORP /DE/
Common Stock
M - Exercise 3,000 13,038 29.89
2018-10-31 2018-10-29 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
A - Award 10,549 10,549
2018-08-01 2018-07-30 4 CELG CELGENE CORP /DE/
Stock Option (right to buy)
A - Award 10,548 10,548
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
21,938
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
13,762
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
21,938
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
13,762
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
21,938
2018-06-14 3 CELG CELGENE CORP /DE/
Common Stock
13,762
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)